

AVITICOL™

Cholecalciferol 20 000 IU capsules

High-dose Cholecalciferol,
licensed for the treatment
and prevention of
vitamin D deficiency



New AVITICOL™

Licensed, cost effective high-dose Cholecalciferol capsules, indicated for the treatment and prevention of vitamin D deficiency

Dosing Guidance

Adult Treatment dose

40 000 IU (2 capsules)
every week for 7 weeks,
followed by maintenance therapy
of 2-3 capsules (equivalent to
1 400 - 2 000 IU/day) per month,
as directed by your doctor

Adult prevention dose

20 000 IU (1 capsule)
every 4 weeks, higher doses
may be required in certain
populations or in specific
medical circumstances

AVITICOL™ can
be used in adolescents,
adults, and the elderly

[SmPC 2014]

AVITICOL™ is
a hard gelatin
liquid-filled capsule,
which is associated with
more consistent and stable
Cholecalciferol dosing

[SmPC 2014]

[In-house data 2014]

Prescribe with confidence

Adverse reactions following treatment with Aviticol™
are uncommon or rare *[SmPC 2014]*

Aviticol™ is arachis (peanut) oil-free so can be used by patients
with peanut allergies *[SmPC 2014]*

Pricing of AVITICOL™

AVITICOL™ 20 000 IU
1 x 30 capsules = **£29.00**

Treatment dose {SmPC 2014}	2 x capsules per week	£1.93
Prevention dose {SmPC 2014}	1 x capsule per month	£0.97

All costs rounded to nearest penny

Licensed High-Dose Products Comparison

Product	Loading dose	Capsules*/ ampoules** required	Total cost of loading dose £
Aviticol™ 20 000 IU	280 000 IU	14*	13.53
Plenachol® 20 000 IU	280 000 IU	14*	19.25
Invita® 25 000 IU	300 000 IU	12**	17.80
Invita® 25 000 IU	400 000 IU	16**	23.73

[Chemist & Druggist 2014] [Invita D3® SmPC 2014] [Plenachol® SmPC 2014]

All costs rounded to nearest penny

AVITICOL™ is now available to order
via all mainline wholesalers



References

- [Chemist & Druggist 2014] Chemist & Druggist. December 2014
- [In-house data 2014] Colonis Pharma. Comparative analytical study of the actual drug content vs stated amount of various high strength cholecalciferol nutritional dosage forms. 2014.
- [Invita D3® SmPC 2014] Consilient Health Limited. Invita D3® SmPC. 2014.
- [Plenachol® SmPC 2014] Auden McKenzie Limited. Plenachol® SmPC. 2014.
- [SmPC 2014] Colonis Pharma. Aviticol™ Summary of Product Characteristics. 2014.

AVITICOL™

Cholecalciferol 20 000 IU capsules

Product name: Avitico™ 20 000 IU Capsules

Composition: Each capsule contains 20 000 IU cholecalciferol (equivalent to 500 µg vitamin D₃).

Indication: The treatment and prevention of vitamin D deficiency in adults and adolescents

Dosage and administration: Adults Posology - Treatment of vitamin D deficiency: 40 000 IU (2 capsules) every week for 7 weeks, followed by maintenance therapy of 2-3 capsules (equivalent to 1 400 - 2 000 IU/day) per month, as directed by your doctor. Follow-up serum 25(OH)D measurements should be made approximately three to four months after initiating maintenance therapy to confirm that the target level has been achieved.
Prevention of vitamin D deficiency: 20 000 IU every 4 weeks (1 capsule), higher doses may be required in certain populations or in specific medical circumstances, please refer to the current Summary of Product Characteristics for further information.

Paediatric Posology (12-18 years) - Prevention of vitamin D deficiency: 20 000 IU (1 capsule) every 6 weeks.
Treatment of vitamin D deficiency: 20 000 IU (1 capsule) once every 2 weeks for 6 weeks. Not recommended for children under 12 years or during pregnancy and breastfeeding.

Contraindications: Hypersensitivity to the active substance (cholecalciferol) or to any of the excipients; hypercalcaemia and/or hypercalciuria; nephrolithiasis; hypervitaminosis; severe renal impairment.

Warnings and precautions: Medical supervision is required whilst on treatment to prevent hypercalcaemia.

Patients from populations at high risk of vitamin D deficiency may require higher doses and monitoring of serum 25(OH)D. Use with caution in patients with impaired renal function; monitor the effect on calcium and phosphate. Patients with a tendency to form calcium-containing renal calculi should not take this medicine. Caution is required in patients receiving treatment with cardiac glycosides for cardiovascular disease due to increased calcium levels. Use with caution in patients with sarcoidosis due to risk of increased vitamin D metabolism. Allowances should be made for vitamin D-containing medicines and supplements. If calcium supplementation is required it should be given under close medical supervision. Please refer to the current Summary of Product Characteristics for further information.

Undesirable effects: Uncommon ($\geq 1/1,000$; $< 1/100$): hypercalcaemia and hypercalciuria. Rare ($\geq 1/10,000$; $< 1/1,000$): pruritus, rash, urticaria

NHS price: £29.00 per pack of 30 capsules

Supply Classification: POM

Marketing Authorisation Holder: Colonis Pharma Limited, Hanover Place, 8 Church Road, Royal Tunbridge Wells, Kent, TN1 1JP, United Kingdom

MA number: PL 41344/0001

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Colonis Pharma Limited, Hanover Place, 8 Church Road, Royal Tunbridge Wells, Kent, TN1 1JP, United Kingdom or medinfo@colonis.co.uk

Date of preparation: October 2014